Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.
about
The management of glaucoma and intraocular hypertension: current approaches and recent advancesSynergistic Effect of Artificial Tears Containing Epigallocatechin Gallate and Hyaluronic Acid for the Treatment of Rabbits with Dry Eye SyndromeCytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells.NC-1059: a channel-forming peptide that modulates drug delivery across in vitro corneal epitheliumIncidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications.Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome.Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy.Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells.Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.Effect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometry.Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.Sphingosine-1 phosphate prevents ethanol-induced corneal epithelial apoptosis.In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis).Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells.Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cellsThe leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride-induced murine dry eye model.Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%).Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment.Analysis of the effects of preservative-free tafluprost on the tear proteome.Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.Free radicals and the pH of topical glaucoma medications: a lifetime of ocular chemical injury?Changes in corneal parameters at confocal microscopy in treated glaucoma patients.Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.Apoptosis in the iris and trabecular meshwork of medically treated and untreated primary open angle glaucoma patients.Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells.Conjunctival markers as predictable markers for preoperative glaucoma assessment.In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells.Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients
P2860
Q22305849-DA24C547-2CB1-4530-8BB6-E297B7FAC740Q28552083-462EF11B-3474-441F-991D-097EEF1E696BQ33510968-3D0AD827-1EF7-413E-B91F-D3A7E7EA6309Q33582539-5F3A7E77-8D46-4E57-804C-04AB480CB4EDQ33819802-17E7D49E-478B-4B08-847E-952840E3D47BQ33831032-220839B8-361C-47C0-AE59-71E9292B6C1AQ33914619-F57E5964-A71A-4FC8-A257-C69B6278894BQ34245277-678460B9-8D4C-47B8-898E-83E58E0986FEQ35227003-8F357A39-7D54-4354-BEC5-2D37017B7181Q35550289-C15F4694-AC12-4D28-8063-285DCCAC166BQ35589561-7EB926D5-4F1F-4D57-B632-667456D462AAQ35919202-26176D4A-357D-4C3A-B3DA-4B7F6D09529AQ36898923-C5D19D9C-A9DE-436D-B910-112F2693BE99Q37689508-307860E9-FFAF-41A1-B9B0-2EB01CF8E66AQ39177865-D6D5214B-CDB1-42F6-918A-C0A7E53CEDCDQ39346376-A4882577-E541-4E00-BFF3-57B1569DBE20Q39820355-9FA5F122-B0A6-42A4-AA78-D2AA45ABD0FBQ41352665-57E4F8A1-898D-4B84-B48E-26C06F78F4C9Q41573602-39C67129-5383-4C27-9DD8-A73F0CE30043Q41668980-0B135EEA-E9F2-4CAD-8147-9A35980FDEDCQ41911324-69323645-26E3-4099-B5E8-27E630769B22Q42040480-53E3D74C-986D-4C1A-9E4C-4996426A9EEFQ42075931-3D7A0499-0358-494A-A8A8-53F6A02B8074Q42181227-316D70F6-E765-42B0-9A51-470CF7BBF36AQ42272983-1955D73A-6678-4533-92F9-75D072916D6EQ42794581-8381F6E0-057F-47D2-B461-5218A32C3100Q42841007-DF895567-CF81-46AD-8336-9ACDB900C111Q42975877-317AE475-E0B7-41F4-A4B8-25006093AA11Q43096347-BC9CDFB6-8ACC-4F55-94A5-9DAF48439FA8Q58915054-EF98FD02-77FC-40A4-91D1-33C5CBA78B65
P2860
Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Toxicity of preserved and unpr ...... o model of conjunctival cells.
@en
type
label
Toxicity of preserved and unpr ...... o model of conjunctival cells.
@en
prefLabel
Toxicity of preserved and unpr ...... o model of conjunctival cells.
@en
P2093
P1433
P1476
Toxicity of preserved and unpr ...... ro model of conjunctival cells
@en
P2093
C Debbasch
J M Warnet
M De Saint Jean
P356
10.1076/0271-3683(200002)20:2;1-D;FT085
P577
2000-02-01T00:00:00Z